A new clinical trial is recruiting!  The SYNAPSE - CMT Clinical Trial.

A new clinical trial (NCT06482437) focusing on Charcot-Marie-Tooth Disease (CMT) is now enrolling!

If you or a loved one has been diagnosed with CMT as a part of the impacts of your DYNC1H1 mutation, this study might be of interest. Note that anyone who experiences motor or sensory neuropathy likely qualifies as having CMT type 2O (the letter “o”, not zero). Talk with your doctor to see if you may qualify.

This study aims to characterize the changes in walking, running, and sit-to-stand actions in addition to any potential side effects of the new drug. The drug is designed to improve communication between nerves and muscles. For more information, visit the study’s webpage on the Charcot Marie Tooth Association’s website: SYNAPSE - CMT Clinical Trial.

Key Details:

This is an interventional study researching the efficacy, safety and tolerability of a new medication, NMD670.

Eligibility: It is open to most individuals between 18-70 years old with Type 1 and 2 CMT who are able to walk (ambulatory). Many individuals with DYNC1H1-related disorders qualify as having CMT.

Who is doing the research: The drug is being developed by NMD Pharma in collaboration with the Charcot Marie Tooth Association. Locations: 18 locations in the US, Belgium, Denmark, France, and Spain, detailed below.

If you or someone you know with CMT is interested in learning more, please click to visit the clinicaltrials.gov website for this study (NCT06482437), or contact the research team directly through the contact information provided on the clinicaltrials.gov page. For convenience, this information is also included below:

United States:

Kansas City, Kansas

Boston, Massachusetts

Columbia, Missouri

New York, New York

Rochester, New York

Columbus, Ohio

Austin, Texas

Spokane, Washington

Belgium

Leuven, Belgium

Liege, Belgium

Denmark

Aarhus, Denmark

Copenhagen, Denmark

France

Marseille, France, 13005

Nantes, France

Nice, France, 06001

Paris, France, 94275

Spain

Barcelona, Spain, 8035

Valencia, Spain, 46026

Next
Next

Case Study: Bone Cancer in a Teen with a DYNC1H1-Related Disorder